Abstract 1651P
Background
The exact origin and associated prognosis of periampullary adenocarcinoma might be challenging to determine, especially in bulky tumours, due to the destruction of normal periampullary anatomy and the extension of the tumour beyond a single periampullary structure. Periampullary carcinomas are typically divided into pancreatobiliary and intestinal types according to histological differentiation. The aim of this study was to determine the prognostic value of this histological differentiation by comparing various clinic-pathological prognostic factors and surgical outcome in periampullary carcinoma cases that underwent pancreaticoduodenectomy.
Methods
From May 2018 to April 2021, 60 consecutive cases of periampullary carcinoma who underwent pancreaticoduodenectomy were included in this study. Cases were divided into two groups: pancreatobiliary and intestinal types. Various clinical and histopathological prognostic variables were analysed, and the association of these variables with pancreatobiliary and intestinal variants of periampullary carcinoma was determined using Chi-square and Fischer’s exact tests.
Results
20 cases were included in the pancreatobiliary group, and 40 cases were included in the intestinal group. These groups were comparable in terms of age, sex, nutritional status, and bilirubin levels. Pancreatobiliary type was more frequently associated with nodal disease (p<0.01), lymphovascular invasion (p<0.01) and perineural invasion (p=0.018). Post-operative morbidity was significantly higher in the pancreatobiliary group (p=0.043). Table: 1651P
S.No. | Variable | Periampullary Carcinoma | x2 | p-value | ||
Pancreatobiliary Type | Intestinal Type | |||||
1 | Age (years) | <60 | 15 | 32 | 0.196 | 0.658 |
>60 | 5 | 8 | ||||
2 | Sex | Male | 12 | 19 | 0.834 | 0.361 |
Female | 8 | 21 | ||||
3 | Comorbidity | Yes | 6 | 16 | 0.574 | 0.449 |
No | 24 | 24 | ||||
4 | Bilirubin (mg/dl) | <5 | 8 | 8 | 2.73 | 0.099 |
>5 | 12 | 32 | ||||
5 | Albumin (g/dl) | < 3 | 8 | 11 | 0.96 | 0.326 |
> 3 | 12 | 29 | ||||
6 | Pancreas Texture | Firm | 10 | 21 | 0.03 | 0.855 |
Soft | 10 | 19 | ||||
7 | MPD | <3mm | 6 | 5 | 2.73 | 0.99 |
>3mm | 14 | 35 | ||||
8 | Tumor size | >2cm | 8 | 21 | 0.834 | 0.361 |
<2cm | 12 | 19 | ||||
9 | Nodal status | Positive | 12 | 10 | 7.03 | 0.008 |
Negative | 8 | 30 | ||||
10 | Lymphovascular Invasion | Present | 12 | 9 | 8.24 | 0.004 |
Absent | 8 | 31 | ||||
11 | Perineural Invasion | Present | 7 | 4 | 5.57 | 0.018 |
Absent | 13 | 36 | ||||
12 | Grade | 1 | 10 | 15 | 0.857 | 0.355 |
2/3 | 10 | 25 | ||||
13 | Post-operative Morbidity | Yes | 11 | 08 | 4.10 | 0.043 |
No | 9 | 32 |
Conclusions
After pancreaticoduodenectomy, periampullary cancer of the pancreatobiliary type is linked to worse post-operative outcome and unfavourable histopathological prognostic markers. Therefore, after surgery, these cases should follow management algorithms with aggressive adjuvant therapy protocols.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22